Jiahui Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiahui Guo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Daliu Min
Department of oncology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Feng Liu
Department of Oncology, Shanghai 9th People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
1 shared publication - Feng-Hou Gao
Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, P.R. China
1 shared publication Hai‐Yun Fang
Department of Oncology, Shanghai 9th People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
1 shared publicationJiamin Zhang
Department of oncology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationJun‐Mei Yang
Department of Clinical Laboratory Children's Hospital Affiliated to Zhengzhou University Zhengzhou China
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Cell Death & Disease
ZC3HAV1 promotes osteosarcoma metastasis through TSC1 mRNA destabilization and mTORC1 pathway activation
Pulmonary metastasis is the leading cause of mortality in osteosarcoma patients, yet the molecular mechanisms that sustain invasive malignancy within metastatic niches remain poorly understood. Through analysis of single-cell transcriptomic data from osteosarcoma lung metastases and clinical survival datasets, this study identifies a pro-invasive malignant cell state associated with poor prognosis and nominates ZC3HAV1 as a top candidate gene. Functional experiments demonstrate that ZC3HAV1 promotes osteosarcoma cell migration, invasion, and lung metastatic colonization both in vitro and in vivo. Mechanistically, the ZC3HAV1 encoded RNA binding protein ZAP forms a complex with the RNA helicase DHX30 to bind the 3’UTR of the tumor suppressor TSC1 mRNA, destabilizing the transcript and thereby relieving TSC mediated inhibition of mTORC1 signaling, which in turn activates a pro-metastatic transcriptional program. Clinically, elevated ZC3HAV1 expression correlates with increased mTORC1 pathway activity and heightened sensitivity to rapamycin treatment. These findings not only establish ZC3HAV1 as a key driver of osteosarcoma metastasis but also reveal a novel paradigm in which tumor cells hijack an evolutionarily conserved antiviral RNA decay machinery to fuel metastatic progression. This work identifies ZC3HAV1 as a predictive biomarker and provides a translational rationale for mTORC1 targeted therapy in ZC3HAV1 high osteosarcoma patients.
- 29 September 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessZC3HAV1 promotes osteosarcoma metastasis through TSC1 mRNA destabilization and mTORC1 pathway activation
Pulmonary metastasis is the leading cause of mortality in osteosarcoma patients, yet the molecular mechanisms that sustain invasive malignancy within metastatic niches remain poorly understood. Through analysis of single-cell transcriptomic data from osteosarcoma lung metastases and clinical survival datasets, this study identifies a pro-invasive malignant cell state associated with poor prognosis and nominates ZC3HAV1 as a top candidate gene. Functional experiments demonstrate that ZC3HAV1 promotes osteosarcoma cell migration, invasion, and lung metastatic colonization both in vitro and in vivo. Mechanistically, the ZC3HAV1 encoded RNA binding protein ZAP forms a complex with the RNA helicase DHX30 to bind the 3’UTR of the tumor suppressor TSC1 mRNA, destabilizing the transcript and thereby relieving TSC mediated inhibition of mTORC1 signaling, which in turn activates a pro-metastatic transcriptional program. Clinically, elevated ZC3HAV1 expression correlates with increased mTORC1 pathway activity and heightened sensitivity to rapamycin treatment. These findings not only establish ZC3HAV1 as a key driver of osteosarcoma metastasis but also reveal a novel paradigm in which tumor cells hijack an evolutionarily conserved antiviral RNA decay machinery to fuel metastatic progression. This work identifies ZC3HAV1 as a predictive biomarker and provides a translational rationale for mTORC1 targeted therapy in ZC3HAV1 high osteosarcoma patients.
- 6 July 2020
- Published by Wiley in Cell Biochemistry and Function
- Vol. 38 (8) , 1100-1110
MicroRNA‐92b acts as an oncogene by targeting PTEN/AKT in NSCLC
MicroRNAs can act as tumour suppressors or oncogenes by regulating cellular differentiation, proliferation and apoptosis, and the dysregulation of miRNA is involved in the occurrence and development of NSCLC. Here, we provided evidence that miR‐92b as an oncogene in NSCLC by targeting PTEN/AKT. We found that miR‐92b was up‐regulated in human NSCLC tissues and cell lines. MiR‐92b knockdown suppressed the NSCLC cells proliferation and migration in both in vivo and in vitro models. Conversely, miR‐92b overexpression induced an aggressive phenotype. Moreover, miR‐92b‐mediated regulation of NSCLC cell proliferation and migration depended on binding to PTEN mRNA, which then led to the degradation of PTEN and activation of the downstream AKT signalling pathway. Overall, this study revealed the oncogenic roles of miR‐92b in NSCLC by targeting PTEN/AKT, and provided novel insights for future treatments of NSCLC patients.Significance of the study: MiR‐92b was up‐regulated in human NSCLC tissues and cell lines. Our study demonstrated that miR‐92b as an oncogene in NSCLC by targeting PTEN/AKT in both in vivo and in vitro models and provided novel insights for future treatments of NSCLC patients.
- 6 July 2020
- Published by Wiley in Cell Biochemistry and Function
- Vol. 38 (8) , 1100-1110
MicroRNA‐92b acts as an oncogene by targeting PTEN/AKT in NSCLC
MicroRNAs can act as tumour suppressors or oncogenes by regulating cellular differentiation, proliferation and apoptosis, and the dysregulation of miRNA is involved in the occurrence and development of NSCLC. Here, we provided evidence that miR‐92b as an oncogene in NSCLC by targeting PTEN/AKT. We found that miR‐92b was up‐regulated in human NSCLC tissues and cell lines. MiR‐92b knockdown suppressed the NSCLC cells proliferation and migration in both in vivo and in vitro models. Conversely, miR‐92b overexpression induced an aggressive phenotype. Moreover, miR‐92b‐mediated regulation of NSCLC cell proliferation and migration depended on binding to PTEN mRNA, which then led to the degradation of PTEN and activation of the downstream AKT signalling pathway. Overall, this study revealed the oncogenic roles of miR‐92b in NSCLC by targeting PTEN/AKT, and provided novel insights for future treatments of NSCLC patients.Significance of the study: MiR‐92b was up‐regulated in human NSCLC tissues and cell lines. Our study demonstrated that miR‐92b as an oncogene in NSCLC by targeting PTEN/AKT in both in vivo and in vitro models and provided novel insights for future treatments of NSCLC patients.